Compare CZFS & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | OBIO |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 238.3M |
| IPO Year | 1995 | 2020 |
| Metric | CZFS | OBIO |
|---|---|---|
| Price | $62.88 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 2.7K | ★ 236.8K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 30.26 | ★ 33.13 |
| EPS | ★ 2.16 | N/A |
| Revenue | $9,881,000.00 | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.64 | $12.43 |
| P/E Ratio | $29.72 | ★ N/A |
| Revenue Growth | 2.82 | ★ 1169.22 |
| 52 Week Low | $49.99 | $2.20 |
| 52 Week High | $69.58 | $5.42 |
| Indicator | CZFS | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 45.37 |
| Support Level | $56.79 | $3.77 |
| Resistance Level | $68.35 | $4.18 |
| Average True Range (ATR) | 1.40 | 0.18 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 61.55 | 34.57 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.